DanDrit Biotech USA Inc. filed an application to list its common shares on the Nasdaq Capital Market following the acquisition of privately held Enochian Biopharma Inc.
The Danish biopharmaceutical company will change its name to Enochian BioSciences Inc. and relocate its headquarters to Los Angeles. It is currently listed on the OTC Pink market.
DanDrit specializes in developing immunotherapies for various types of cancer and is currently working on innovative treatments for HIV and colon cancer.